Kiniksa Pharmaceuticals International, plc

KNSA

Kiniksa Pharmaceuticals International, plc

KNSA

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-05-01Shares Purchased (TTM):0Shares Sold (TTM):710,843

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:43,250,876Shares Outstanding:76,516,535Institutional Ownership Pct.:56.52%

Earnings Market Reaction:

Filing Date:2026-04-28Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Common Class B1	0	0	-16	0	16	0	0	0	16	16	0	0
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	190	166	175	192	157	184	97	99	141	108	118	113
Short Term Investments	278	248	177	116	111	60	126	119	72	98	83	72
Accounts Receivable Net Current	23	16	52	32	40	42	25	20	16	21	3	25
Inventory Net	73	55	41	48	22	26	29	35	27	31	26	24
Prepaid Expense And Other Assets Current	30	43	30	32	25	20	34	27	14	18	26	12
Assets Current	594	527	476	420	356	332	311	301	271	276	256	246
Property Plant And Equipment Net	2	2	2	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	9	10	10	10	10	10	11	12	12	12	13	13
Other Assets Noncurrent	11	11	8	8	8	10	8	8	4	1	2	2
Finite Lived Intangible Assets Net	15	15	16	16	16	16	17	17	17	17	18	18
Deferred Income Tax Assets Net	194	198	201	206	208	211	208	204	215	219	194	204
Assets	825	764	712	661	599	581	555	542	520	526	483	484
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	24	2	6	9	2	2	8	7	6	8	1	1
Accrued Liabilities Current	33	42	31	36	22	32	40	33	45	28	41	35
Contract With Customer Liability Current	-	-	-	-	-	-	-	0	0	0	3	5
Operating Lease Liability Current	3	3	3	3	2	2	2	2	2	2	2	2
Other Liabilities Current	21	22	21	18	17	16	16	11	11	8	6	5
Liabilities Current	157	139	124	118	97	101	96	84	64	64	53	47
Liabilities Noncurrent
Contract With Customer Liability Noncurrent	32	32	32	32	32	32	12	12	12	12	12	12
Operating Lease Liability Noncurrent	6	7	7	7	8	8	9	9	10	10	11	11
Other Liabilities Noncurrent	25	19	15	9	5	2	2	2	2	2	2	2
Liabilities	220	196	177	166	142	142	118	107	88	87	78	73
Stockholders Equity
Additional Paid In Capital	1,046	1,030	1,012	990	970	960	949	935	928	917	908	901
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	-0	-0	-0	-0	-0	-0	-0	0	-0	0
Retained Earnings Accumulated Deficit	-440	-462	-476	-495	-513	-521	-512	-500	-496	-478	-503	-489
Stockholders Equity	606	568	535	495	457	438	437	435	432	439	405	412
Liabilities And Stockholders Equity	825	764	712	661	599	581	555	542	520	526	483	484
Common Class A	1	0	-0	-0	1	0	-0	-0	2	36	-0	-0
Common Class B	0	0	-2	0	2	0	0	0	2	2	0	-0
Common Class A1	0	0	-13	0	13	0	0	0	13	17	0	0
Common Stock Par Or Stated Value Per Share	-	0	-	-	-	0	-	-	-	0	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-1.13%	2.34%	18.76%	-	-	-	-	-	-	-	-	-
2025	3.90%	9.89%	12.13%	11.13%	16.63%	27.23%	5.45%	9.54%	-0.05%	5.93%	3.22%	29.91%
2024	12.27%	6.59%	20.44%	0.35%	-2.51%	2.51%	-8.53%	-11.50%	-20.31%	18.46%	2.48%	33.11%
2023	3.76%	14.01%	14.97%	-7.67%	-11.96%	-17.62%	0.13%	14.36%	18.37%	-1.92%	-16.94%	-2.90%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	3.79	3.79	3.85	3.57	3.66	3.30	3.24	3.57	4.21	4.34	4.79	5.18
Quick Ratio	3.14	3.09	3.27	2.88	3.17	2.84	2.59	2.84	3.57	3.58	3.82	4.42
Working Capital	437.56M	387.99M	351.94M	302.48M	258.64M	231.18M	215.35M	216.73M	206.38M	212.63M	202.64M	198.57M
Leverage & Debt
Debt to Equity	0.36	0.35	0.33	0.34	0.31	0.32	0.27	0.25	0.20	0.20	0.19	0.18
Debt Ratio	0.27	0.26	0.25	0.25	0.24	0.24	0.21	0.20	0.17	0.17	0.16	0.15
Efficiency & Turnover
Asset Turnover TTM	1.06	1.01	0.94	0.88	0.86	0.76	0.74	0.66	0.63	0.55	0.53	0.81
Days Sales Outstanding TTM	15.32	15.44	23.39	18.05	21.26	27.16	13.27	24.29	14.16	22.91	10.42	21.09
Receivables Turnover TTM	23.83	23.64	15.61	20.22	17.17	13.44	27.51	15.03	25.77	15.93	35.03	17.30
Per Share Metrics
Diluted EPS TTM	0.89	0.75	0.45	0.06	-0.22	-0.60	-0.13	-0.14	0.12	0.20	-0.10	3.23
Free Cash Flow Per Share TTM	2.15	1.84	1.36	0.91	0.60	0.36	0.15	0.43	0.30	0.19	-0.04	0.61
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	89.31%	88.54%	87.52%	85.93%	85.83%	85.61%	86.31%	87.73%	87.75%	87.64%	87.73%	89.89%
Operating Profit Margin TTM	12.36%	11.40%	6.38%	0.85%	-3.28%	-10.78%	-6.83%	-8.12%	-10.12%	-9.32%	-7.73%	13.57%
Net Profit Margin TTM	9.69%	8.71%	6.01%	0.90%	-3.52%	-10.21%	-2.36%	-3.02%	2.87%	5.21%	-2.69%	82.35%
Growth Metrics
Net Revenue Growth (1Y)	56.71%	60.09%	55.68%	56.18%	59.45%	56.60%	54.41%	20.69%	27.69%	22.74%	40.50%	212.04%
Net Income Growth (1Y)	-531.02%	-236.61%	-496.10%	-146.82%	-295.95%	-406.68%	35.51%	-104.42%	-95.59%	-92.32%	-104.69%	-306.35%
EPS Growth (1Y)	-509.22%	-231.50%	-480.25%	-145.27%	-290.52%	-400.82%	32.59%	-104.36%	-95.65%	-92.39%	-104.64%	-304.50%
Valuation Metrics
P/E TTM	50.43	51.87	80.77	424.23	-95.19	-32.71	-197.67	-129.59	161.11	87.25	-182.18	4.26
P/B TTM	6.08	5.39	5.42	4.11	3.53	3.22	4.10	3.05	3.23	2.80	3.01	2.39
P/S TTM	4.89	4.52	4.85	3.84	3.35	3.34	4.67	3.91	4.62	4.55	4.90	3.51
Market Cap	3.68B	3.06B	2.90B	2.03B	1.61B	1.41B	1.79B	1.33B	1.39B	1.23B	1.22B	984.45M
Enterprise Value	3.49B	2.90B	2.73B	1.84B	1.46B	1.23B	1.70B	1.23B	1.25B	1.12B	1.10B	871.88M
Calculated Values
Free Cash Flow TTM	164.23M	136.42M	101.73M	66.49M	43.73M	25.41M	11.10M	30.31M	21.37M	13.17M	-2.71M	42.36M
Net Debt	-189.95M	-165.60M	-174.86M	-192.04M	-157.13M	-183.58M	-97.38M	-99.27M	-141.08M	-107.95M	-117.83M	-112.57M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-01Sale

Owner: Paolini, John F.

Title: CHIEF MEDICAL OFFICER

Shares: 58,424

Price/Share: $53.78

Value: $3,142,042.72

Shares Owned: 65,623

Relationship: Officer

Ownership: Direct

2026-05-01Sale

Owner: Patel, Sanj K

Title: CHAIRMAN & CEO

Shares: 48,565

Price/Share: $54.02

Value: $2,623,481.30

Shares Owned: -

Relationship: Director,Officer

Ownership: Direct

2026-04-30Sale

Owner: Patel, Sanj K

Title: CHAIRMAN & CEO

Shares: 2,141

Price/Share: $54.01

Value: $115,635.41

Shares Owned: -

Relationship: Director,Officer

Ownership: Direct

2026-04-28Sale

Owner: Quart, Barry D

Title: -

Shares: 13,099

Price/Share: $50.10

Value: $656,259.90

Shares Owned: 12,546

Relationship: Director

Ownership: Direct

2026-04-09Sale

Owner: Megna, Michael R

Title: CHIEF ACCOUNTING OFFICER

Shares: 6,625

Price/Share: $46.69

Value: $309,321.25

Shares Owned: 27,418

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-01	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	58,424	53.78	$3,142,042.72	65,623	4
2026-05-01	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	48,565	54.02	$2,623,481.30	0	4
2026-04-30	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	2,141	54.01	$115,635.41	0	4
2026-04-28	Quart, Barry D	Director	-	Direct	Sale	13,099	50.10	$656,259.90	12,546	4
2026-04-09	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	6,625	46.69	$309,321.25	27,418	4
2026-04-09	Moat, Ross	Officer	CHIEF OPERATING OFFICER	Direct	Sale	1,703	46.69	$79,513.07	12,029	4
2026-04-06	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	7,278	50.01	$363,972.78	0	4
2026-04-06	Moat, Ross	Officer	CHIEF OPERATING OFFICER	Direct	Sale	2,367	48.58	$114,988.86	12,029	4
2026-04-06	Quart, Barry D	Director	-	Direct	Sale	6,901	50.00	$345,050.00	12,546	4
2026-03-09	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	36,722	45.91	$1,685,907.02	12,086	4
2026-03-02	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	40,000	45.00	$1,800,000.00	61,324	4
2026-02-12	Quart, Barry D	Director	-	Direct	Sale	2,690	45.00	$121,050.00	12,546	4
2026-02-09	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	17,845	43.28	$772,331.60	12,086	4
2026-02-04	Quart, Barry D	Director	-	Direct	Sale	2,602	45.02	$117,142.04	12,546	4
2026-01-08	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	12,000	41.89	$502,680.00	19,086	4
2025-12-15	Quart, Barry D	Director	-	Direct	Sale	20,129	41.51	$835,554.79	12,546	4
2025-12-15	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	12,048	41.56	$500,714.88	16,666	4
2025-12-08	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	42,841	41.49	$1,777,473.09	31,086	4
2025-11-26	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	200	42.89	$8,578.00	22,714	4
2025-11-17	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	12,470	40.69	$507,404.30	22,714	4
2025-11-12	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	19,900	40.94	$814,706.00	31,086	4
2025-10-31	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	82,542	37.14	$3,065,609.88	61,324	4
2025-10-28	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	100	41.00	$4,100.00	31,086	4
2025-10-22	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	97,390	38.83	$3,781,653.70	111,794	4
2025-10-20	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	50,490	39.02	$1,970,119.80	27,046	4
2025-10-14	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	12,368	37.82	$467,757.76	28,684	4
2025-09-29	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	42,000	38.33	$1,609,860.00	34,552	4
2025-09-15	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	16,400	36.72	$602,208.00	34,552	4
2025-09-05	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	13,389	35.66	$477,451.74	44,452	4
2025-09-04	Moat, Ross	Officer	CHIEF CORP. & COMM. OFFICER	Direct	Sale	3,523	35.31	$124,397.13	9,415	4
2025-09-03	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	15,091	35.50	$535,730.50	44,452	4
2025-09-03	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	11,000	34.84	$383,240.00	38,011	4
2025-08-18	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	16,200	34.11	$552,582.00	40,215	4
2025-08-14	Malley, Thomas	Director	-	Direct	Sale	78,233	33.09	$2,588,729.97	12,546	4
2025-08-06	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	29,325	32.55	$954,528.75	57,403	4
2025-08-05	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	138,614	33.55	$4,650,499.70	49,915	4
2025-08-04	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	18,889	32.89	$621,259.21	27,009	4
2025-08-04	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	17,000	32.35	$549,950.00	33,041	4
2025-07-14	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	18,900	28.72	$542,808.00	49,163	4
2025-06-16	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	17,300	28.28	$489,244.00	61,563	4
2025-06-11	Quart, Barry D	Director	-	Direct	Sale	12,336	30.39	$374,891.04	12,546	4
2025-06-11	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	45,042	30.51	$1,374,231.42	72,363	4
2025-06-03	Moat, Ross	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	27,594	29.02	$800,777.88	9,415	4
2025-06-03	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	18,299	28.80	$527,011.20	27,009	4
2025-06-03	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	15,211	28.75	$437,316.25	32,546	4
2025-05-28	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	62,116	27.33	$1,697,630.28	96,674	4
2025-05-20	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	2,349	27.02	$63,469.98	96,674	4
2025-05-19	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	12,000	26.41	$316,920.00	72,363	4
2025-05-13	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	2,872	27.03	$77,630.16	96,674	4
2025-05-09	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	6,029	27.05	$163,084.45	96,674	4
2025-05-07	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	200	27.00	$5,400.00	57,403	4
2025-05-07	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	17,647	26.69	$470,998.43	32,546	4
2025-05-05	Moat, Ross	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	6,272	28.00	$175,616.00	9,415	4
2025-05-01	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	25,141	27.80	$698,919.80	27,009	4
2025-05-01	Moat, Ross	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	23,234	28.02	$651,016.68	9,415	4
2025-04-21	Moat, Ross	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	18,259	20.29	$370,475.11	9,415	4
2025-04-14	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	12,000	20.46	$245,520.00	77,363	4
2025-03-20	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	15,944	23.11	$368,465.84	23,382	4
2025-03-19	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	8,879	23.10	$205,104.90	23,382	4
2025-03-12	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	9,051	22.45	$203,194.95	26,528	4
2025-03-12	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	36,372	22.25	$809,277.00	22,958	4
2025-03-10	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	12,409	21.06	$261,333.54	76,566	4
2025-02-10	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	14,000	19.57	$273,980.00	81,975	4
2025-01-13	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	14,000	18.60	$260,400.00	88,975	4
2024-12-16	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	23,017	20.44	$470,467.48	95,975	4
2024-12-09	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	18,860	21.38	$403,226.80	22,958	4
2024-12-05	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,123	21.25	$23,863.75	22,958	4
2024-11-29	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	9	22.45	$202.05	26,528	4
2024-11-18	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	17,000	21.04	$357,680.00	102,975	4
2024-11-06	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	89,561	23.00	$2,059,903.00	79,551	4
2024-10-15	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	17,000	26.87	$456,790.00	109,975	4
2024-09-23	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	17,500	24.99	$437,325.00	116,975	4
2024-09-03	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	60,692	26.61	$1,615,014.12	52,038	4
2024-09-03	Moat, Ross	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	68,506	26.61	$1,822,944.66	21,736	4
2024-08-27	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	17,500	26.91	$470,925.00	119,911	4
2024-07-23	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Direct	Sale	136,124	25.10	$3,416,712.40	63,012	4
2024-07-23	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	24,248	24.79	$601,107.92	19,253	4
2024-07-23	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	22,000	26.59	$584,980.00	47,803	4
2024-03-07	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Indirect	Sale	65,012	21.02	$1,366,552.24	0	4
2024-03-06	Patel, Sanj K	Director,Officer	CHAIRMAN & CEO	Indirect	Sale	5,582	21.00	$117,222.00	65,012	4
2024-03-01	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	9,659	21.45	$207,185.55	17,588	4
2024-03-01	Tessari, Eben	Officer	CHIEF OPERATING OFFICER	Direct	Sale	1,189	22.03	$26,193.67	122,847	4
2024-03-01	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	18,844	21.77	$410,233.88	44,892	4
2024-02-27	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,156	21.03	$213,580.68	44,892	4
2024-01-03	Ragosa, Mark	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	12,000	20.00	$240,000.00	15,632	4
2024-01-02	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	16,670	19.17	$319,563.90	17,005	4
2023-12-19	Megna, Michael R	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	9,316	19.13	$178,215.08	17,005	4
2023-12-07	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	28,600	17.68	$505,648.00	44,892	4
2023-09-05	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	400	17.53	$7,012.00	44,892	4
2023-07-25	Paolini, John F.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	29,000	18.98	$550,420.00	41,910	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

56.52%

Inst. Shares: 43,250,876

Shares Outstanding: 76,516,535

2025-12-31

54.70%

Inst. Shares: 40,584,664

Shares Outstanding: 74,200,924

2025-09-30

51.99%

Inst. Shares: 38,842,601

Shares Outstanding: 74,714,846

2025-06-30

51.53%

Inst. Shares: 37,843,671

Shares Outstanding: 73,438,530

2025-03-31

52.89%

Inst. Shares: 38,422,785

Shares Outstanding: 72,647,121

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	43,250,876	76,516,535	56.52%
2025-12-31	40,584,664	74,200,924	54.70%
2025-09-30	38,842,601	74,714,846	51.99%
2025-06-30	37,843,671	73,438,530	51.53%
2025-03-31	38,422,785	72,647,121	52.89%
2024-12-31	38,098,943	71,424,159	53.34%
2024-09-30	39,087,951	71,726,685	54.50%
2024-06-30	34,850,646	71,004,640	49.08%
2024-03-31	38,289,876	70,633,023	54.21%
2023-12-31	33,538,743	70,058,952	47.87%
2023-09-30	34,104,095	70,186,016	48.59%
2023-06-30	31,226,508	69,918,287	44.66%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Kiniksa Pharmaceuticals International, plc (KNSA) — SEC Financial Statements & Analysis

Kiniksa Pharmaceuticals International, plc (KNSA) is a pharmaceutical preparations company. Kiniksa Pharmaceuticals International, plc trades on Nasdaq as: KNSA. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Kiniksa Pharmaceuticals International, plc reported a 56.71% year-over-year revenue growth, a Gross Profit Margin of 89.31% (TTM), a Debt-to-Equity ratio of 0.36x, a Price-to-Sales (P/S) ratio of 4.89x (TTM), a Price-to-Book (P/B) ratio of 6.08x (TTM), at a market cap of $3.68B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 56.71%
Gross Profit Margin TTM: 89.31%
Debt To Equity: 0.36x
P/S TTM: 4.89x
P/B TTM: 6.08x
Market Cap: $3.68B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Kiniksa Pharmaceuticals International, plc in?

Kiniksa Pharmaceuticals International, plc (KNSA) operates in the Pharmaceutical Preparations industry.

What is KNSA's market cap?

Kiniksa Pharmaceuticals International, plc (KNSA) has a market capitalization of $3.68B as of 2026-03-31.

What is KNSA's P/E ratio?

Kiniksa Pharmaceuticals International, plc (KNSA)'s trailing twelve month P/E ratio is 50.43x as of 2026-03-31.

What exchange does KNSA trade on?

Kiniksa Pharmaceuticals International, plc (KNSA) trades on the Nasdaq.